Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app help heal diabetic foot wounds?

NCT ID NCT07815275

Symptom relief Sponsor: Oman Ministry of Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing DiaFootCare, a mobile app that teaches foot self-care, sends medication and care reminders, guides users through taking wound photos, and shares information with pharmacists. The trial enrolls 139 adults aged 40 to 60 with diabetes and an active foot ulcer at the National Diabetes and Endocrine Centre in Oman. Half use the app alongside usual care for three months, and half receive usual care alone. The study measures whether wounds close completely and tracks wound size, blood sugar control, and how people use the app.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DiaFootCare mobile application, a smartphone tool for diabetic foot self-care education, reminders, wound photos, and pharmacist support
What this could lead to
If the app helps, it could give people with diabetic foot ulcers a low-cost way to track their wound, stick to care routines, and stay in touch with pharmacists between clinic visits.
What could go wrong
This is a single-centre study in Oman with 139 adults, so results may not apply elsewhere. An app can only help if people use it consistently, and some participants may find wound photos or daily reminders hard to keep up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 139 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Adults aged 40 to 60 years. * Diagnosed with type 1 or type 2 diabetes mellitus. * Have an active diabetic foot ulcer. * Receiving diabetic foot care at the National Diabetes and Endocrine Centre in Oman. * Have access to a compatible smartphone and internet connection. * Able to understand Arabic and use the DiaFootCare application after receiving instructions. * Willing and able to provide written informed consent and complete the three-month follow-up. Exclusion Criteria: * Severe cognitive, visual, physical, or communication impairment that prevents use of the application or completion of study assessments. * A diabetic foot condition requiring immediate hospitalization or urgent major surgical intervention. * Unable or unwilling to complete the three-month follow-up. * Concurrent participation in another intervention study that could affect the study outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Diabetic Foot Medication Adherence type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus Diabetic foot ulcer (DFU)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Diabetes and Endocrine Centre

    Muscat, 119, Oman

More trials for these conditions

Other studies related to the condition(s) this trial covers.